Teleflex Inc Stock Price, News & Analysis

Teleflex reported fourth quarter 2020 revenues of $711.2 million, a 4.4% increase year-over-year, with adjusted diluted EPS of $3.25, down 0.9%. Full-year revenues fell 2.2% to $2.537 billion, alongside a 27.6% drop in GAAP diluted EPS to $7.10. The company estimates the COVID-19 pandemic had a $61 million negative impact on fourth-quarter revenue and $281 million for the full year. Looking ahead, 2021 guidance projects 10-11.5% revenue growth and adjusted diluted EPS between $12.50 and $12.70.

Teleflex Incorporated (NYSE: TFX) announced the submission of a Biologics License Application (BLA) for its investigational freeze dried plasma (FDP) candidate to the FDA. This candidate, developed in collaboration with the U.S. Army Medical Materiel Development Activity, aims to enhance emergency medical responses to battlefield injuries. The application is eligible for priority review and accelerated approval, facilitating potential rapid availability. The FDP is not yet FDA-approved. The announcement underscores Teleflex's innovation focus in medical technologies.

Teleflex Incorporated (NYSE: TFX) will be represented by CEO Liam Kelly at the Barclays Global Healthcare Conference on March 9, 2021, at 10:55 am ET. A live audio webcast of the event will be accessible on the investor section of Teleflex's website, along with a presentation slide deck. Teleflex specializes in medical technologies aimed at enhancing health and quality of life through innovative solutions in various medical fields, including vascular access and emergency medicine. For more information, visit www.teleflex.com.

Teleflex Incorporated (NYSE: TFX) has successfully completed patient enrollment ahead of schedule in its clinical study evaluating specialty catheters and coronary guidewires for Chronic Total Occlusion (CTO) percutaneous coronary interventions. The study enrolled 150 patients across 13 US sites, concluding three months early. CTOs affect nearly 20% of patients undergoing coronary angiography, often leading to severe ischemia and cardiac dysfunction. The study aims to assess device performance and safety, with expectations for results to inform clinical practices in CTO procedures.

Teleflex Incorporated (NYSE: TFX) announced that Chairman, President, and CEO Liam Kelly will speak at the Raymond James 42nd Annual Institutional Investors Conference on March 2, 2021, at 12:30 p.m. ET. A live audio webcast and accompanying slides will be accessible on the investor section of Teleflex's website. Teleflex is dedicated to enhancing healthcare through innovative medical technologies across various specialties.

Teleflex Incorporated (NYSE: TFX) will announce its Q4 2020 and full-year financial results on February 25, 2021, before market open. A live conference call will occur at 8:00 a.m. ET on the same day, accessible via audio webcast on the company’s website. An audio replay will be available from 11:00 a.m. ET on February 25, 2021, until 11:00 a.m. ET on March 2, 2021. Teleflex is a leading provider of medical technologies aimed at enhancing health and quality of life.

Teleflex Incorporated (NYSE: TFX) announced new data published in European Urology Focus, indicating that the Prostatic Urethral Lift (PUL) procedure using the UroLift® System significantly preserves and improves sexual function compared to medical treatment for benign prostatic hyperplasia (BPH). The study showed a 17% and 21% increase in erectile function at 1 and 2 years, respectively, and substantial improvements in ejaculatory function over four years. Meanwhile, medication treatments generally led to declines in sexual function. These findings underscore UroLift's benefits for BPH patients.

Teleflex expands its ErgoPack® Complete system by introducing new Arrow® Multi-Lumen Access Catheter (MAC) and Percutaneous Sheath Introducer (PSI) systems, enhancing vascular access solutions. Building on the October 2020 launch of the ErgoPack® Complete CVC System, these innovations incorporate clinician-inspired features such as a GlideWheel™ Advancer and kink-resistant guidewire. These enhancements aim to reduce catheter-related complications, adhering to CDC and SHEA guidelines while offering broad-spectrum antimicrobial protection against pathogens.